Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.81 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.81 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.81 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.74 |
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 1/20 | 0.70 |
| ▸ | PLG | P00747 | 1/20 | 0.70 |
| ▸ | PLAU | P00749 | 1/20 | 0.70 |
| ▸ | PLAT | P00750 | 1/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802454 | 1.00 | CSNK2A2 (0.81) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL11974092 | 0.97 | PLCG2 (0.78) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL2131615 | 0.93 | DAPK3 (0.75) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL2131623 | 0.93 | DAPK3 (0.75) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL4691058 | 0.93 | DAPK3 (0.75) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL24418241 | 0.89 | PLCG2 (0.68) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL10602166 | 0.89 | ALDH1A1 (0.72) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL13656064 | 0.89 | ALDH1A1 (0.72) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL22819049 | 0.89 | PLCG2 (0.68) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 | |
| SCHEMBL6789114 | 0.89 | PLCG2 (0.68) | CSNK2A2CSNK2BCSNK2A1PLCG2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | WARNER-LAMBERT COMPANY LLC | 2004-09-16 | — | — | US | claimed |
| US-10774036-B2 | Process for early sacubitril intermediates | NOVARTIS AG (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | CHIRAL QUEST (SUZHOU) CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| WO-2017059759-A1 | PROCESS FOR PREPARATION OF N-BOC BIPHENYL ALANINOL | CHIRAL QUEST (SUZHOU) CO., LTD. (CN) | 2017-04-13 | — | — | WO | disclosed |
| EP-2480523-B1 | PROCESS FOR MANUFACTURE OF N-ACYLBPHENYL ALANINE | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2017-03-01 | — | — | EP | disclosed |
| EP-3119742-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX Holdings B.V. (NL) | 2017-01-25 | — | — | EP | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| WO-2015024991-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015024991-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2015-02-26 | — | — | WO | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| US-20140142320-A1 | Process for the Manufacture of N-acylbiphenyl alanine | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-20140142320-A1 | Process for the Manufacture of N-acylbiphenyl alanine | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-20130172572-A1 | Process for Manufacture of N-acylbiphenyl alanine | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172572-A1 | Process for Manufacture of N-acylbiphenyl alanine | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-07-04 | — | — | US | disclosed |
| WO-2013026773-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM IP ASSETS B.V. (NL) | 2013-02-28 | — | — | WO | disclosed |
| WO-2011035569-A1 | PROCESS FOR MANUFACTURE OF N-ACYLBPHENYL ALANINE | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774036-B2 | Process for early sacubitril intermediates | MME, ACE, DNPEP | CSNK2A2 1689/4885CSNK2B 989/4885CSNK2A1 1625/4885 |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | RABL6, PF4, SPIN4 | CSNK2A2 4236/4885CSNK2B 4169/4885CSNK2A1 4632/4885 |
| US-20040180943-A1 | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis | APP, PSEN1, PSEN2 | CSNK2A2 1982/4885CSNK2B 1874/4885CSNK2A1 1986/4885 |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | CYP2B6, CYP2A6, CYP2D6 | CSNK2A2 4708/4885CSNK2B 4681/4885CSNK2A1 4729/4885 |
| US-20140142320-A1 | Process for the Manufacture of N-acylbiphenyl alanine | ANPEP, DNPEP, ENPEP | CSNK2A2 2436/4885CSNK2B 1576/4885CSNK2A1 2452/4885 |
| US-20130172572-A1 | Process for Manufacture of N-acylbiphenyl alanine | ANPEP, DNPEP, RNPEP | CSNK2A2 2403/4885CSNK2B 1553/4885CSNK2A1 2496/4885 |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | MME, ACE, DNPEP | CSNK2A2 1303/4885CSNK2B 759/4885CSNK2A1 1254/4885 |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | CYP1B1, UGT1A1, UGT2B7 | CSNK2A2 4241/4885CSNK2B 4136/4885CSNK2A1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.